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Abstract
Background: Artemisinin-based combination therapy (ACT) is currently the most effective medicine for the
treatment of uncomplicated malaria. Artemisinin has previously been shown to increase the clearance of
Plasmodium falciparum in malaria patients with haemoglobin E trait, but it did not increase parasite inhibition in an
in vitro study using haemoglobin AS erythrocytes. The current study describes the efficacy of artemisinin derivatives
on P. falciparum clearance in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD), a haemoglobin
enzyme deficiency, not yet studied in the same context, but nonetheless is a common in malaria endemic areas,
associated with host protection against uncomplicated and severe malaria. The impact of G6PD deficiency on
parasite clearance with ACT treatment was compared between G6PD-deficient patients and G6PD-normal group.
Methods: Blood samples from children and adults participants (1 to 70 years old) with uncomplicated P.
falciparum malaria residing in Kambila, Mali were analysed. Study participants were randomly assigned to receive
either artemether-lumefantrine (Coartem®) or artesunate plus mefloquine (Artequin™). A restriction-fragment length
polymorphism analysis of PCR-amplified DNA samples was used to identify the (A-) allele of the gene mutation
responsible for G6PD deficiency (G6PD*A-). 470 blood samples were thus analysed and of these, DNA was
extracted from 315 samples using the QIAamp kit for PCR to identify the G6PD*A- gene.
Results: The DNA amplified from 315 samples using PCR showed that G6PD*A- deficiency was present in 56
participants (17.8%). The distribution of the specific deficiency was 1%, 7% and, 9.8% respectively for homozygous,
hemizygous, and heterozygous genotypes. Before treatment, the median parasitaemia and other baseline
characteristics (mean haemoglobin, sex and age groups) between G6PD deficiency (hemizygous, heterozygous, and
homozygous) and G6PD-normal participants were comparable (p > 0.05). After treatment, parasite clearance did
not change significantly whether the participants were G6PD deficient or G6PD normal on day 1 (OR = 1.3; CI =
0.70-2.47; p > 0.05) and on day 2 (OR = 0.859; CI = 0.097-7.61; p > 0.05).
Conclusions: The presence of G6PD deficiency does not appear to significantly influence the clearance of P.
falciparum in the treatment of uncomplicated malaria using ACT.
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In a race to combat the ever increasing resistance of
Plasmodium falciparum to older anti-malarial drugs,
artemisinin, a natural product found in the leafy por-
tions of Artemisia annua (qinghao) and its derivatives,
have emerged as alternative drugs for the treatment of
falciparum malaria [1]. Artemisinin derivatives are ses-
quiterpenoides with an endoperoxide, which is the
essential component of the anti-malarial activity. With
their structural distinction from all other anti-malarial,
artemisinins have so far been shown to be effective
against multidrug-resistant strains of P. falciparum.T h e
use of artemisinin-based combination therapy (ACT) is
associated with a rapid clearance of the parasite and a
low probability of drug-resistant parasite emergence [2].
ACT is currently recommended by World Health Orga-
nization (WHO) for treating uncomplicated falciparum
malaria. Several reports evaluating the efficacy of ACT
have confirmed its efficacy and safety. Studies by Falade
et al in Nigeria showed a 28-day cure rate of about 95%
with artemether-lumefantrine (AL) [3] and 93% for arte-
sunate-amodiaquine (ASAQ) [4]. Karema et al also
reported day 28 cure rates of 95.2% and 92.0% for dihy-
droartemisinin/piperaquine (Artekin) and ASAQ,
respectively, in Rwanda [5].
Studies have also shown P. falciparum susceptibility to
anti-malarial drugs to correlate with abnormal haemo-
globins. A clinical study in Thailand first suggested that
haemoglobin E trait (with characteristically increased
oxidative activity due to excess a-globin chains) inter-
acts with artemisinin derivatives to enhance P. falci-
parum clearance in malaria patients with haemoglobin
E trait compared to patients treated with other anti-
malarials [6]. Another study found a reduced chloro-
quine and artemisinin efficacy against P. falciparum in
a-thalassemia [7]. Other studies found no differences in
parasite susceptibility to chloroquine in Hb AS and Hb
AA red blood cells in vitro [8]. More recently, an in
vitro study has demonstrated no evidence of elevated
artemisinin activity on P. falciparum in haemoglobin AS
erythrocytes [9]. These conflicting data on the activity of
artemisinin on P. falciparum in abnormal haemoglobin
carriers make it imperative to assess the efficacy of ACT
in G6PD deficient patients in Mali, where this haemo-
globinopathy is common. As far as the literature is con-
cerned, no such studies have been done to study the
efficacy of artemisinin against P. falciparum in G6PD
deficient patients. G6PD variants correlates with histori-
cal distribution of malaria [10] and the mutant allele
(A-) encoding G6PD with 10%-50% of abnormal enzyme
activity is widespread in Africa [11]. The aim of this
study was to determine the clearance of P. falciparum
and treatment efficacy in uncomplicated malaria as
assessed by WHO 28-day protocol using ACT. The
study hypothesis was that treatment with ACT may
induce faster parasite clearance in G6PD deficient
patients compared to G6PD normal patients.
Methods
Setting and study design
The study participants were selected from a randomized
study conducted in Kambila village. The study partici-
pants were randomized to receive artemisinin-based
combination therapy artemether-lumefantrine (Coar-
tem®) or artesunate plus mefloquine (Artequin™). The
G6PD mutant gene was identified by nested PCR per-
formed on stored blood samples (filter paper dot). The
study hypothesis was based on fact that P. falciparum in
G6PD deficient patients would clear faster after ACT
initiation compared to normal patients. A nested case
control design was used to compare G6PD deficient to
G6PD-normal subjects with a ratio of one case for four
controls.
Study population
The study participants were selected from children and
adults (1 to 70 years old) patients who came to the
health centre for care during the study period. Only
patients with uncomplicated malaria who gave their
consent after explanation of study objectives and under-
stood were enrolled into the study. Children were
enrolled after obtaining a written parental or guardian
fully informed consent. Blood samples were collected
from both children and adult patients and were analysed
for G6PD status, and parasite clearance since it has been
shown that parasite clearance is faster in adults than
children [12].
Study site and period
Study was conducted during a malaria transmission sea-
son from August 2004 through January 2005, in Kam-
bila, Mali. Kambila is a peri-urban village of Kati located
about 25 km from Bamako with a population of
approximately 1,500 inhabitants. Malaria in this area is
hyper-endemic and transmission is highly seasonal.
P. falciparum is the predominant infecting species,
accounting for more than 95% of malaria cases [13].
Kambila is one of the Mali malaria research sites where
malaria drug efficacy data are available, and a prevalence
of as high as 17% G6PD deficiency has also been docu-
mented [14].
Sample size
The sample size was computed based on 70% of parasite
clearance observed 24-hours after artesunate/amodia-
quine treatment initiation in a general population at
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endemic area of Mali. Assuming an error risk alpha set
at 0.05, a power of 80%, for one case matched with four
controls and fixing a detectable risk estimate at 3.0
(Odds ratio), we will need 55 samples in the cases group
(G6PD deficient) and 220 in the control group (non
G6PD deficient), rounded up to 56 cases and 259
controls.
Inclusion and exclusion criteria
Participants were included if they fulfilled the following
criteria: 1) weighed ≥ 10 kg; 2) had a P. falciparum
parasite density of between 2,000 and 200,000/μl; 3) had
an auxiliary temperature ≥ 37.5°C; 4) were a resident of
the study site; and 5) could take medication orally.
Persons were excluded if they had symptoms or signs
of severe malaria [15], had a serious disease, had an
allergy to one or more study drugs, had used any com-
ponent of the study drugs within 28 days of enrollment,
or were pregnant (detected either clinically or with a
urine ß-human chorionic gonadotropin test). Commu-
nity permission and individual written informed consent
were provided by a parent or guardian of all participat-
ing children, as described by Diallo et al [16]. Withdra-
wal criteria for the study included (a) protocol violation,
(b) participant withdrawal of consent, and (c) develop-
ment of serious adverse event.
Ethics considerations
The protocol was reviewed and approved by the ethical
committee of the Faculty of Medicine, Pharmacy and
Odonto-Stomatology of the University of Bamako before
starting the randomized clinical trial. Approval letter
from these three Faculty ethical of committees was also
obtained before conducting the molecular analysis for
the G6PD deficiency study.
Laboratory procedures
Giemsa-stained thick blood smears were read by experi-
enced laboratory technicians who were blinded to treat-
ment allocations. Parasite densities were calculated by
counting the number of asexual parasites until 300 leu-
kocytes were observed and then converting that to para-
sites per microlitre of blood, assuming an average
leukocyte count of 7,500/μl. For quality control, 10% of
the slides were selected at random and re-read by
another lab technician who was unaware of the results
of the first reading.
Two methods were used for DNA extraction on blood
spotted filter paper:
(1). An initial extraction was done using methanol. If
no DNA could be extracted from blood samples or if
the results of the PCR were conflicting, DNA was
extracted using the QIAamp kit [17]. (2). If after an
initial extraction using methanol yielded no results, or if
the results yielded were conflicting, the QIAamp kit [17]
was used to extract DNA.
The (A_) allele of the gene responsible for G6PD defi-
ciency was determined by restriction fragment length
polymorphism analysis of PCR-amplified DNA samples.
Under conditions intended to eliminate the risk of
cross-contamination and with appropriate water-only
negative controls, exon 4 of G6PD was amplified using a
nested PCR protocol: 1 μgo fg e n o m i cD N Aw a sf i r s t
amplified using primers 5’-GTCTTCTGGGTCAG
GGAT-3’ (forward) and 5’-GGAGAAAGCTCTCTCT
CC-3’ (reverse). Denaturation at 94°C for 2 min was fol-
lowed by 45 cycles of denaturation at 94°C for 30 s,
annealing at 60°C for 30 s, extension at 72°C for 60 s,
and final extension at 72°C for 4 min. Nested amplifica-
tion was performed using primers 5’-CCTGTTCCC-
TCTGCCACA-3’ (forward) and 5’-GGGGGTCTC
AAGAAGTAC-3’ (reverse). Denaturation at 94°C for 2
min was followed by 35 cycles of denaturation at 94°C
for 30 s, annealing at 60°C for 60 s, extension at 72°C
for 30 s, and a final extension at 72°C for 4 min. Ampli-
fication products were recovered with separate pipettes
in laboratory areas apart from the PCR-preparation
bench and digested with the restriction endonuclease
NlaIII [18] or its isoschizomer Hsp92II [19] to detect
the G6PD*A mutation at nucleotide position 202. Com-
plete cutting of PCR product identified hemizygous
males and homozygous females and cutting of half of
the product identified heterozygous females.
Participants surveillance
S t u d yp a r t i c i p a n t sw e r ee x a m i n e da t1 ,2 ,3 ,7 ,1 4 ,2 1 ,
and 28 days after enrollment or at any time if they did
not feel well. A finger skin puncture was used to obtain
blood for a thick blood smear and a filter paper dot (for
future parasite DNA extraction) at each follow-up visit.
Study endpoints
The primary study endpoint was the time to parasitae-
mia disappearance from day 1 after treatment initiation.
Parasitaemia clearance was defined as the parasitaemia
disappearance at day 1, day 2 and up to day 28 after
treatment. Proportion of gametocytes carriers at day
3 was defined as the percent of subjects carrying game-
tocytes that day regardless of their gametocyte carriage
on day 0. The efficacy of ACT was assessed as an ade-
quate clinical and parasitological response at day 28
according to WHO 2003 guideline [20].
Statistical analysis
Data were double-entered, validated using Microsoft
Access (Microsoft Corporation, Washington, USA), and
analysed with STATA version 10.0 (STATA Corporation,
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were used to compare proportions between groups.
Mann-Whitney test or Kruskal Wallis test were used as
appropriate to assess differences of median parasitaemia
between groups for continuous variables. Logistic regres-
sion was used to control confounding factors, the odds
ratio and exact 95% CIs were calculated. A P value (two-
sided) < 0.05 was considered as statistically significant.
Results
The DNA amplified from 315 samples out of the 470
samples using PCR showed that G6PD*A- deficiency
was present in 56 participants (17.8%). The distribution
o ft h es p e c i f i cd e f i c i e n c yw a s1 % ,7 %a n d ,9 . 8 %r e s p e c -
tively for homozygous, hemizygous, and heterozygous
genotypes. The mean haemoglobin and the mean body
temperature were compared and no difference was seen
between G6PD deficient genotype and normal genotype
(p > 0.05) (Table 1).
T h eG 6 P Dd e f i c i e n c yg e n o t y p e sw e r ed i s t r i b u t e d
equally between age groups (p = 0.2). The risk estimate
of P. falciparum clearance at day 1, for homozygous,
hemizygous or heterozygous G6PD deficiency versus
G6PD-normal was not significant (Table 2). When med-
ian parasitaemia at day 0 for the normal G6PD was
compared to the G6PD non-normal in general, there
was no difference (p = 0.1).
From day 0 to day 3 the comparison of median para-
site density and parasite clearance with respect to the
different G6PD genotypes including the normal group
didn’ts h o wa n ys i g n i f i c a n td i f f e r e n c eb e t w e e ng r o u p s
(Figure 1).
Data were analysed by age groups (age groups as indi-
cated in table 1) to assess age specific effect on parasite.
The study results did not show significant differences
between patients with G6PD deficiency compared to
patients without the deficiency on day 1. The ACT efficacy
treatment on day 28 was similar in the G6PD deficient
group compared to the non-deficient group (Table 3).
Gametocytes carriage at day 3 was not influenced by
G6PD deficiency when the G6PD-normal group was com-
pared to G6PD deficient group (Table 4).
Discussion
The purpose of this study was to determine the com-
bined effect of G6PD deficiency and ACT treatment
(artemether-lumefantrine and artesunate plus meflo-
quine) on parasite clearance in patients with uncompli-
cated falciparum malaria. Data were analysed by age
groups to assess age-specific effect on parasite clearance
in patients with G6PD deficiency, since studies have
shown that parasite clearance was faster in adults than
in children [12,21]. The current study shows no signifi-
cant difference in parasite clearance between G6PD defi-
cient patients compared to patients without the
deficiency when adjusted for age effect.
The overall prevalence of G6PD deficiency was 17.8% is
comparable to other authors finding reported elsewhere
in Africa where the prevalence is from 0% to 25% [22].
The prevalence of 22.2% was reported in Congo [23]
Genotype frequency was 9.8% (31/315), 7% (22/315), and
1% (3/315) for female heterozygous, male hemizygous
and female homozygous respectively. The study findings
are similar to those reported in other studies where they
also observed genotype frequencies of 12% (36/303) for
female heterozygous, 8% (25/303) for male hemizygous
and < 1% (1/303) for homozygous females [24].
Parasite clearance between the different genotypes at
day 0 was not statistically significant as median parasi-
taemia between abnormal and normal G6PD genotypes
Table 1 Distribution of G6PD deficiency genotypes according to age groups, body temperature and hemoglobin level
at enrollment
G6PD Genotypes Temperature Haemoglobin
Hb/dl
Age groups
Mean°C (Range) Mean (Range) < 5 years 5-10 years 11-17 years >17 years Total Number
n (%) n (%) n (%) n (%) n (%)
Homozygous 38.0 (0.8) 11.4 (1.6) 1 (0,9) 2 (1,3) 0 (0) 0 (0) 3 (1)
Hemizygous 38.5 (2.8) 11.2 (5.3) 5 (4.7) 13 (8.7) 3 (6,1) 1 (10) 22 (7)
Heterozygous 38.5 (2.3) 11.4 (8.0) 6 (5,6) 14(9,4) 9 (18,4) 2 (20) 31 (9,8)
Normal 38.5 (2.9) 11.2 (9.1) 95 (88.8) 120 (80.5) 37 (75.5) 7 (70.0) 259 (82,2)
Total 38.5 (2.9) 11.2 (9.1) 107 (100) 149 (100) 49 (100) 10 (100) 315 (100)
Fisher exact test p = 0.2 for G6PD Genotypes within age groups.
ANOVA p ≥ 0.05 for G6PD Genotypes and body temperature mean or haemoglobin mean.
Table 2 Risk estimate of P. falciparum clearance at day 1,
G6PD deficiency genotypes versus G6PD-normal
n OR (95% IC) P
Genotypes of G6PD
Homozygous 3 0.894 (0.079-10.12) 0.93
Hemizygous 22 0.842 (0.33-2.15) 0.72
Heterozygous 31 0.695 (0.303-1.59) 0.40
Normal 258 1 (Reference)
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hemizygous and heterozygous had a tendency of ele-
vated median parasitaemia. Similar observation with
geometric mean parasitaemia was also reported else-
where [24].
A comparison of the median parasitaemia at day 0
between normal G6PD patients and G6PD deficient
patients in general showed no difference (median para-
site of 20212 parasites/μl versus 15975 parasites/μl
respectively; p = 0.1). The study results did not confirm
findings by Nkuo-Akenji et al., 2004 who showed a sig-
nificant difference in the mean parasite density in G6PD
enzyme deficient group compared to the G6PD normal
group. That study found a mean parasite density of 3.7
(± 3.9, SD) for enzyme deficient individuals and 4.4 (±
5.0, SD) for enzyme active individuals (p < 0.05) [25].
The study results have shown that G6PD deficiency
had no significant association with parasite clearance and
median parasitaemia from day 0 to day 3 (Figure 1). The
detectable risk estimate of three-fold parasite clearance
used to calculate the sample size in this study may also
be too high risk estimate, which may have resulted in a
small simple size and, therefore, underpowered the study
to detect any small differences in parasite clearance that
Figure 1 Clearance and density of P. falciparum from day 0-day 3, G6PD deficiency genotypes versus G6PD-normal.
Table 3 Association between G6PD deficiency and 28-day
follow-up PCR corrected ACT efficacy
Efficacy Hemizygous
n (%)
Heterozygous
n (%)
Homozygous
n (%)
Normal
n (%)
Total
n (%)
Cured* 20 (100) 29 (96.6) 3 (100.0) 237
(98.02)
299
(98.03)
Failure
cases
0 (0.0) 1 (3.33) 0 (0.0) 5 (1.98) 6
(1.97)
Total 20 (100) 30 (100) 3 (100) 252
(100)
305
(100)
*Adequate Clinical and Parasitological Response
Fisher exact test = 0.685
Table 4 Comparison of proportions of gametocytes
carriers at day 3, G6PD deficient patients versus G6PD-
normal patients
Proportion of gametocytes carriers
G6PD Status Gametocytes (-) Gametocytes (+) Total
n (%) n (%) n
Deficiency 54 (96.4) 2* (3.6) 56
Normal 252 (97.7) 6 (2.3) 258
Total 306 (97.5) 8 (2.5) 314
Fisher exact test p = 0.63
*The two cases occurred in heterozygous genotype deficiency
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cient G6PD patients on day 1 or day 2.
Other factors such as the molecular biology methods
used to determine G6PD deficiency used in our study
may also undermine the role of G6PD deficiency in
parasite clearance. Enzyme assay appears to better
reflect the biological effects of the G6PD enzyme more
than genotyping. This was suggested in a recent study
which showed that among female G6PD- deficient
patients, but not male patients, whose genotype was also
confirmed by enzymatic methods to have low enzyme
activity as shown by enzyme assay were significantly
protected from uncomplicated malaria, while patients
with higher levels of enzyme activity were not protected
against uncomplicated malaria [26].
No significant association between ACT efficacy and
G6PD deficiency was seen in our data (Table 4).
Although host immune response could play a role in
treatment efficacy as other studies have demonstrated
[27], the fast parasite clearance and treatment efficacy
observed in this study regardless of the G6PD deficiency
status is similar to what has been observed in other
ACT trials in Mali [13,28]. This is indicative of the high
efficacy rates in general of the ACT in Mali.
The possibility of reduced susceptibility of parasites to
ACT in G6PD deficient patients could not also be ruled
out since in a study with a-thalassemia patients, it was
hypothesized that the infected variant erythrocytes could
not accumulate as much drug as infected normal ery-
throcytes (7, 9). Furthermore, the authors had shown
that the reduction in artemisinin accumulation in
infected variant erythrocytes was due partly to competi-
tion with uninfected erythrocytes for the drug, and
partly to the lower drug accumulation inside the parasite
[7,29]. Therefore, a possible lower drug accumulation in
parasites in G6PD deficient red cells could be a disad-
vantage to G6PD-deficient carriers. This effect is how-
ever, yet to be demonstrated in vitro studies.
In contrast another study reported that among hemo-
globin E patients treated with artemisinin derivatives,
the presence of hemoglobin E trait was associated with
an estimated 2.9-fold increase in parasite clearance rate
(95% CI, 1.4-6.3; P=.006) [6].
The present study looked at the role of G6PD
deficiency in gametocyte carriage and found that the
proportion of gametocytes carried was similar in G6PD-
deficient and G6PD-normal individuals after treatment
at day 3. Similar percentage of gametocyte carriage has
also been shown with ACT in the general population in
Mali [13,28].
The clearance of P. falciparum using ACT in G6PD-
deficient patients with uncomplicated malaria may
require both enzymatic assay and genetic analysis of the
mutation to detect and characterize G6PD deficiency. In
clinical trials, whilst enzymatic assays seem to more clo-
sely approximate biologic function and correlate with
protection, genetic analysis may uncover novel variants
causing disease and thereby provide important insights
for treatment of uncomplicated malaria.
The likely explanation for a lack of difference in para-
site clearance time between those with and without
G6PD deficiency is simply that clearance was rapid in
all groups due to the rapid activity of artemisinin deriva-
tive, and that, if there was any difference, it could not be
discriminated with once-daily assessment.
Conclusions
The study findings suggest that G6PD deficiency did not
increase or reduce the parasite clearance and the efficacy
of ACT. The biological assays that detect G6PD enzyme
activity during malaria treatment may reflect the level of
G6PD deficiency and, therefore, may more accurately
assess parasite clearance in the presence of treatment
rather than using PCR methodology to determine G6PD
deficiency as in this study. Other confounding factors
such as other host erythrocyte variants and host relative
immunity may also play a crucial role in G6PD activity.
An in vitro study and in vivo with several daily assess-
ments may be help to understand the interaction
between parasite clearance, ACT and G6PD deficiency.
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